Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Stopped Study was set-up in 2017, even though the protocol was adjusted, it was not possible to find suitable patients.

Conditions

• NSCLC Stage IV

Interventions

• DRUG: combination regimen tremelimumab /durvalumab
• DRUG: platinum-based chemotherapy (SoC)

Sponsor

AIO-Studien-gGmbH

Collaborators

• [object Object]